Is RLAY or JBIO more profitable?

Relay Therapeutics' return on equity of -42.27% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -42.27% -38.67% Jade Biosciences N/A -49.11% -45.62%

Does the media prefer RLAY or JBIO?

In the previous week, Relay Therapeutics had 23 more articles in the media than Jade Biosciences. MarketBeat recorded 25 mentions for Relay Therapeutics and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.45 beat Relay Therapeutics' score of 0.86 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jade Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ELVN or JBIO?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Jade Biosciences N/A N/A -$127.41M -$1.92 N/A

Is ELVN or JBIO more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -18.55% -18.09% Jade Biosciences N/A -49.11% -45.62%

Does the media prefer ELVN or JBIO?

In the previous week, Enliven Therapeutics had 13 more articles in the media than Jade Biosciences. MarketBeat recorded 15 mentions for Enliven Therapeutics and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.45 beat Enliven Therapeutics' score of 0.66 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jade Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, JBIO or CELC?

Celcuity is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jade Biosciences N/A N/A -$127.41M -$1.92 N/A Celcuity N/A N/A -$177.04M -$4.30 N/A

Is JBIO or CELC more profitable?

Jade Biosciences' return on equity of -49.11% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Jade Biosciences N/A -49.11% -45.62% Celcuity N/A -350.78% -41.54%

Does the media favor JBIO or CELC?

In the previous week, Celcuity had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 4 mentions for Celcuity and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.45 beat Celcuity's score of 0.22 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, JBIO or PBLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jade Biosciences N/A N/A -$127.41M -$1.92 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Is JBIO or PBLS more profitable?

Parabilis Medicines' return on equity of 0.00% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jade Biosciences N/A -49.11% -45.62% Parabilis Medicines N/A N/A N/A

Does the media favor JBIO or PBLS?

In the previous week, Parabilis Medicines had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 4 mentions for Parabilis Medicines and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.45 beat Parabilis Medicines' score of 0.65 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, JBIO or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Jade Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jade Biosciences N/A N/A -$127.41M -$1.92 N/A Telix Pharmaceuticals $803.79M 4.93 -$7.12M N/A N/A

Is JBIO or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jade Biosciences N/A -49.11% -45.62% Telix Pharmaceuticals N/A N/A N/A

Does the media prefer JBIO or TLX?

In the previous week, Telix Pharmaceuticals had 12 more articles in the media than Jade Biosciences. MarketBeat recorded 14 mentions for Telix Pharmaceuticals and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.45 beat Telix Pharmaceuticals' score of 0.44 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 3 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Jade Biosciences (JBIO) Competitors

$21.49 +0.15 (+0.70%)

As of 02:47 PM Eastern

Compare

JBIO vs. RLAY, ELVN, CELC, PBLS, and TLX

Should you buy Jade Biosciences stock or one of its competitors? Jade Biosciences's main competitors and comparable companies include Relay Therapeutics (RLAY), Enliven Therapeutics (ELVN), Celcuity (CELC), Parabilis Medicines (PBLS), and Telix Pharmaceuticals (TLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Jade Biosciences compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Relay Therapeutics presently has a consensus target price of $25.92, indicating a potential upside of 31.02%. Jade Biosciences has a consensus target price of $51.75, indicating a potential upside of 143.13%. Given Jade Biosciences' higher possible upside, analysts clearly believe Jade Biosciences is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Jade Biosciences has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$10.35M	418.80	-$276.48M	-$1.57	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

In the previous week, Relay Therapeutics had 23 more articles in the media than Jade Biosciences. MarketBeat recorded 25 mentions for Relay Therapeutics and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.45 beat Relay Therapeutics' score of 0.86 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics' return on equity of -42.27% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Jade Biosciences	N/A	-49.11%	-45.62%

Relay Therapeutics has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

97.0% of Relay Therapeutics shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Relay Therapeutics beats Jade Biosciences on 9 of the 14 factors compared between the two stocks.

How does Jade Biosciences compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Enliven Therapeutics currently has a consensus price target of $75.00, suggesting a potential upside of 22.51%. Jade Biosciences has a consensus price target of $51.75, suggesting a potential upside of 143.13%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Jade Biosciences is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

95.1% of Enliven Therapeutics shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Enliven Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

In the previous week, Enliven Therapeutics had 13 more articles in the media than Jade Biosciences. MarketBeat recorded 15 mentions for Enliven Therapeutics and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.45 beat Enliven Therapeutics' score of 0.66 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics' return on equity of -18.55% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Jade Biosciences	N/A	-49.11%	-45.62%

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

Summary

Enliven Therapeutics and Jade Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Jade Biosciences compare to Celcuity?

Jade Biosciences (NASDAQ:JBIO) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

In the previous week, Celcuity had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 4 mentions for Celcuity and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.45 beat Celcuity's score of 0.22 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celcuity is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Jade Biosciences presently has a consensus price target of $51.75, suggesting a potential upside of 143.13%. Celcuity has a consensus price target of $154.55, suggesting a potential upside of 69.02%. Given Jade Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Jade Biosciences is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

63.3% of Celcuity shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by insiders. Comparatively, 13.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Jade Biosciences' return on equity of -49.11% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-49.11%	-45.62%
Celcuity	N/A	-350.78%	-41.54%

Jade Biosciences has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

Summary

Jade Biosciences beats Celcuity on 10 of the 14 factors compared between the two stocks.

How does Jade Biosciences compare to Parabilis Medicines?

Jade Biosciences (NASDAQ:JBIO) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Jade Biosciences currently has a consensus target price of $51.75, indicating a potential upside of 143.13%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential upside of 7.81%. Given Jade Biosciences' higher probable upside, equities research analysts clearly believe Jade Biosciences is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Parabilis Medicines' return on equity of 0.00% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-49.11%	-45.62%
Parabilis Medicines	N/A	N/A	N/A

In the previous week, Parabilis Medicines had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 4 mentions for Parabilis Medicines and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.45 beat Parabilis Medicines' score of 0.65 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Jade Biosciences and Parabilis Medicines tied by winning 4 of the 8 factors compared between the two stocks.

How does Jade Biosciences compare to Telix Pharmaceuticals?

Jade Biosciences (NASDAQ:JBIO) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Jade Biosciences currently has a consensus target price of $51.75, indicating a potential upside of 143.13%. Telix Pharmaceuticals has a consensus target price of $20.40, indicating a potential upside of 75.09%. Given Jade Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Jade Biosciences is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Telix Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Telix Pharmaceuticals has higher revenue and earnings than Jade Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A
Telix Pharmaceuticals	$803.79M	4.93	-$7.12M	N/A	N/A

In the previous week, Telix Pharmaceuticals had 12 more articles in the media than Jade Biosciences. MarketBeat recorded 14 mentions for Telix Pharmaceuticals and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.45 beat Telix Pharmaceuticals' score of 0.44 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	3 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jade Biosciences has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

Telix Pharmaceuticals' return on equity of 0.00% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-49.11%	-45.62%
Telix Pharmaceuticals	N/A	N/A	N/A

Summary

Jade Biosciences beats Telix Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Jade Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JBIO vs. The Competition

Export

Metric	Jade Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.35B	$3.99B	$7.28B	$12.72B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-11.08	11.76	271.35	24.06
Price / Sales	N/A	1,302.10	605.78	77.99
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	3.16	17.24	11.18	6.39
Net Income	-$127.41M	-$22.72M	$3.46B	$348.39M
7 Day Performance	-9.23%	2.86%	1.95%	1.06%
1 Month Performance	6.00%	9.66%	7.28%	5.22%
1 Year Performance	158.63%	54.43%	24.58%	16.09%

Jade Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JBIO Jade Biosciences	2.3973 of 5 stars	$21.49 +0.7%	$51.75 +140.8%	+159.3%	$1.37B	N/A	N/A	20	Positive News
RLAY Relay Therapeutics	3.3788 of 5 stars	$19.93 -0.7%	$25.58 +28.4%	+426.8%	$4.37B	$15.35M	N/A	330	Analyst Revision
ELVN Enliven Therapeutics	2.862 of 5 stars	$58.06 +0.2%	$72.67 +25.2%	+186.9%	$4.25B	N/A	N/A	50
CELC Celcuity	3.1999 of 5 stars	$86.60 -6.0%	$155.18 +79.2%	+78.4%	$4.22B	N/A	N/A	40
PBLS Parabilis Medicines	2.4407 of 5 stars	$35.67 -4.7%	$41.67 +16.8%	N/A	$4.21B	N/A	N/A	N/A	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JBIO) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jade Biosciences (JBIO) Competitors

JBIO vs. RLAY, ELVN, CELC, PBLS, and TLX

How does Jade Biosciences compare to Relay Therapeutics?

Summary

How does Jade Biosciences compare to Enliven Therapeutics?

Summary

How does Jade Biosciences compare to Celcuity?

Summary

How does Jade Biosciences compare to Parabilis Medicines?

Summary

How does Jade Biosciences compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO vs. The Competition

Jade Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jade Biosciences (JBIO) Competitors

JBIO vs. RLAY, ELVN, CELC, PBLS, and TLX

How does Jade Biosciences compare to Relay Therapeutics?

Do analysts recommend RLAY or JBIO?

Which has better earnings & valuation, RLAY or JBIO?

Does the media prefer RLAY or JBIO?

Is RLAY or JBIO more profitable?

Which has more risk and volatility, RLAY or JBIO?

Do insiders and institutionals believe in RLAY or JBIO?

Summary

How does Jade Biosciences compare to Enliven Therapeutics?

Do analysts prefer ELVN or JBIO?

Do institutionals and insiders hold more shares of ELVN or JBIO?

Which has more volatility and risk, ELVN or JBIO?

Does the media prefer ELVN or JBIO?

Is ELVN or JBIO more profitable?

Which has preferable valuation & earnings, ELVN or JBIO?

Summary

How does Jade Biosciences compare to Celcuity?

Does the media favor JBIO or CELC?

Which has higher earnings and valuation, JBIO or CELC?

Do analysts prefer JBIO or CELC?

Do insiders & institutionals have more ownership in JBIO or CELC?

Is JBIO or CELC more profitable?

Which has more volatility and risk, JBIO or CELC?

Summary

How does Jade Biosciences compare to Parabilis Medicines?

Do analysts rate JBIO or PBLS?

Which has better earnings and valuation, JBIO or PBLS?

Is JBIO or PBLS more profitable?

Does the media favor JBIO or PBLS?

Summary

How does Jade Biosciences compare to Telix Pharmaceuticals?

Do analysts recommend JBIO or TLX?

Which has better valuation & earnings, JBIO or TLX?

Does the media prefer JBIO or TLX?

Which has more risk and volatility, JBIO or TLX?

Is JBIO or TLX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO vs. The Competition

Jade Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools